Bruno M. A., Clarke P. B., Seltzer A., Quirion R., Burgess K., Cuello A. C., Saragovi H. U. (2004). Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA, J Neurosci, 24(37), 8009-18.

Carvajal C. C., Vercauteren F., Dumont Y., Michalkiewicz M., Quirion R. (2004). Aged neuropeptide Y transgenic rats are resistant to acute stress but maintain spatial and non-spatial learning, Behav Brain Res, 153(2), 471-80.

Dal Bo G., St-Gelais F., Danik M., Williams S., Cotton M., Trudeau L. E. (2004). Dopamine neurons in culture express VGLUT2 explaining their capacity to release glutamate at synapses in addition to dopamine, J Neurochem, 88(6), 1398-405.

Doré S., Kofler J., Quirion R. (2004). The insulin-like growth factor-I (IGF-1): A key modulator of neurogenesis and cognitive functions . In Craighead W. E. & Nemeroff C. B. (Eds.) , The Concise Corsini Encyclopedia of Psychology and Behavioral Science (pp. 460-466). J. Wiley.

Dumont Y., Chabot J. G., Quirion R. (2004). Receptor autoradiography as mean to explore the possible functional relevance of neuropeptides: focus on new agonists and antagonists to study natriuretic peptides, neuropeptide Y and calcitonin gene-related peptides, Peptides, 25(3), 365-91.

Dumont Y., Thakur M., Beck-Sickinger A., Fournier A., Quirion R. (2004). Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP, Neuropeptides, 38(4), 163-74.

Emilien G., Durlach C., Minaker K. L., Winblad B., Gauthier S., Maloteaux J. M. (2004). Alzheimer Disease : Neuropsychology and Pharmacology . Birkhauser Boston.

Erkinjuntti T., Roman G., Gauthier S. (2004). Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors, Neurol Res, 26(5), 603-5.

Erkinjuntti T., Roman G., Gauthier S., Feldman H., Rockwood K. (2004). Emerging therapies for vascular dementia and vascular cognitive impairment, Stroke, 35(4), 1010-7.

Evans R. M., Hui S., Perkins A., Lahiri D. K., Poirier J., Farlow M. R. (2004). Cholesterol and APOE genotype interact to influence Alzheimer disease progression, Neurology, 62(10), 1869-71.

Feldman H., Gauthier S., Hecker J., Vellas B., Hux M., Xu Y., Schwam E. M., Shah S., Mastey V. (2004). Economic evaluation of donepezil in moderate to severe Alzheimer disease, Neurology, 63(4), 644-50.

Gaudreault S. B., Chabot C., Gratton A., Poirier J. (2004). The caveolin scaffolding domain modifies 2-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor binding properties by inhibiting phospholipase A2 activity, J Biol Chem, 279(1), 356-62.

Gaudreault S. B., Dea D., Poirier J. (2004). Increased caveolin-1 expression in Alzheimer's disease brain, Neurobiol Aging, 25(6), 753-9.

Gauthier S. (2004). [Treatment of Alzheimer's disease: general methodological aspects], Rev Neurol (Paris), 160(2), 261-4.

Gauthier S., Scheltens Philip, Cummings Jeffrey L. (2004). Alzheimer's Disease and Related Disorders Annual 2004 (pp. 182). Martin Dunitz.

Gauthier S., Touchon J. (2004). Subclassification of mild cognitive impairment in research and in clinical practice . In Gauthier Serge, Scheltens Philip, Cummings Jeffrey L. & Gauthier Serge (Eds.) , Alzheimer's Disease and Related Disorders Annual 2004 (pp. 61-69). Martin Dunitz.

Grundman M., Petersen R. C., Ferris S. H., Thomas R. G., Aisen P. S., Bennett D. A., Foster N. L., Jack C. R., Galasko D. R., Doody R., Kaye J., Sano M., Mohs R., Gauthier S., Kim H. T., Jin S., Schultz A. N., Schafer K., Mulnard R., van Dyck C. H., Mintzer J., Zamrini E. Y., Cahn-Weiner D., Thal L. J. (2004). Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials, Arch Neurol, 61(1), 59-66.

Guevara J., Dilhuydy H., Espinosa B., Delacourte A., Quirion R., Mena R., Joanette Y., Zenteno E., Robitaille Y. (2004). Coexistence of reactive plasticity and neurodegeneration in Alzheimer diseased brains, Histol Histopathol, 19(4), 1075-84.

Han Y. S., Zheng W. H., , Chabot J. G., Quirion R. (2004). Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C, Br J Pharmacol, 141(6), 997-1005.

Kar S., Quirion R. (2004). Amyloid beta peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology, Prog Brain Res, 145, 261-74.